Australian Pharmaceuticals & Biotech Most Popular Stocks

Proteomics International Laboratories

Market Cap: AU$54.8m

Operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia.

Cynata Therapeutics

Market Cap: AU$54.6m

Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.

NeuroScientific Biopharmaceuticals

Market Cap: AU$53.2m

Engages in the research and development of novel peptide-based pharmaceutical products.

Syntara

Market Cap: AU$45.7m

Operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia.

Emyria

Market Cap: AU$45.2m

Engages in delivering and developing of treatments for mental health and select neurological conditions in Australia.

Cleo Diagnostics

Market Cap: AU$45.0m

A biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia.

Vitura Health

Market Cap: AU$44.4m

Engages in the sale and distribution of medicinal cannabis products in Australia.

Prescient Therapeutics

Market Cap: AU$44.2m

A clinical stage oncology company, develops drugs for the treatment of various cancers in Australia.

Little Green Pharma

Market Cap: AU$41.3m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

Cryosite

Market Cap: AU$41.0m

Provides outsourced clinical trials logistic services in Australia.

Argenica Therapeutics

Market Cap: AU$32.8m

A biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia.

OncoSil Medical

Market Cap: AU$32.5m

A medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma.

BCAL Diagnostics

Market Cap: AU$26.3m

A screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer.

Noxopharm

Market Cap: AU$26.0m

A biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia.

IDT Australia

Market Cap: AU$25.4m

Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the Unites States.

Avecho Biotechnology

Market Cap: AU$20.6m

A biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India.

Immuron

Market Cap: AU$20.4m

A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.

Tissue Repair

Market Cap: AU$16.9m

A clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia.

Althea Group Holdings

Market Cap: AU$16.9m

Manufactures, distributes, and sells cannabis-based medicines and recreational cannabis products in Australia, the United Kingdom, Canada, Germany, and Ireland.

Nanollose

Market Cap: AU$16.5m

A biomaterials company, engages in the research and development, and promotion of microbial cellulose technologies in Australia.

Firebrick Pharma

Market Cap: AU$16.5m

Engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally.

Algorae Pharmaceuticals

Market Cap: AU$14.3m

A pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand.

Invex Therapeutics

Market Cap: AU$12.0m

A biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.

Cambium Bio

Market Cap: AU$11.9m

A clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications.

Percheron Therapeutics

Market Cap: AU$10.9m

Engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia.

Cann Group

Market Cap: AU$10.0m

Engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe.

Chimeric Therapeutics

Market Cap: AU$9.8m

A clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia.

Invion

Market Cap: AU$9.4m

A clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia.

Patrys

Market Cap: AU$9.2m

Develops and commercializes antibody technologies for the treatment of cancer in Australia.

ECS Botanics Holdings

Market Cap: AU$8.4m

Engages in the cultivation, manufacture, and sale of medicinal cannabis products in Australia and internationally.

Memphasys

Market Cap: AU$7.9m

Develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia.

Argent BioPharma

Market Cap: AU$7.5m

A clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally.

Epsilon Healthcare

Market Cap: AU$7.2m

Operates as a healthcare and pharmaceuticals company primarily in Australia.

Acrux

Market Cap: AU$5.7m

Develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.

Genetic Technologies

Market Cap: AU$5.7m

A molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.

Zelira Therapeutics

Market Cap: AU$4.8m

A biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States.